Saama Appoints Ian Holmes, Ph.D., to Swiss Board of Directors
Source:

Saama Technologies

January 14, 2021
  • Four-decade life sciences industry veteran 
  • Wide spectrum of pharma and CRO experience
  • Extensive global clinical trial operations and management expertise

CAMPBELL, CA – (January 14, 2021) – Saama Technologies, Inc. (“Saama”), the #1 AI clinical analytics platform company, announced today that Ian Holmes, Ph.D., has joined its Swiss Board of Directors, effective January 1, 2021. Based in Zurich, Dr. Holmes brings over 40 years of drug research and development experience and expertise to Saama’s European presence.

Most recently Dr. Holmes held the position of Senior Vice President of Corporate Development at the CRO PharmaNet, now Syneos Health Clinical. As a member of the PharmaNet Global Executive Committee, he was charged with effecting the geographical expansion and globalization of the company, with emphasis on Europe, Asia, Australasia, and Latin America. His responsibilities included affiliate and office establishment and the hiring of initial local clinical research and trial management teams. Dr. Holmes’s CRO experience also includes serving as Executive Director of Clinical Research Europe at Zurich-based CRO Covance CAPS AG, previously G.H. Besselaar Associates, Corning Pharmaceutical Services. In this capacity he fulfilled various clinical trial management and directorship operational roles on a global basis. Dr. Holmes’s extensive pharmaceutical company experience includes tenures at both Sandoz LTD and Merck and Co. where he respectively led a preclinical thrombosis research laboratory and managed clinical pharmacology trials in Europe.

“2020 underscored the critical need for ongoing collaboration between the great scientific minds of biopharma and the great engineering minds of technology to address and solve human disease,” said Suresh Katta, Founder and CEO of Saama Technologies. “Saama will leverage and integrate Ian’s very welcomed perspective, experience and advice into our strategic plans to ensure we continue to be a valued and highly-sought-after partner to the life sciences industry.”  

 “Saama’s impressive trajectory and offerings make it an ideal – and necessary – collaborator to ensure effective and accelerated clinical therapeutic research,” said Dr. Holmes. “I look forward to helping inform and support Saama’s continued growth and expanding partnerships with both pharmaceutical companies and CROs.”

About Saama Technologies, Inc.

Saama is the #1 AI clinical analytics platform company, enabling the life sciences industry to conduct faster and safer clinical development and regulatory programs. Today, over 50 biotech companies use Saama’s award-winning Life Science Analytics Cloud (LSAC) platform on more than 1,500 studies, including many of the top 20 pharmaceutical companies. LSAC’s rich applications facilitate an unprecedented, authoritative oversight of comprehensive clinical research data, enabling companies to file New Drug Applications (NDAs) more efficiently and bring drugs to market faster. Discover more at www.saama.com and follow Saama @SaamaTechInc.  

Media Contact 

Gregory T. Simpson

Saama Technologies

gregory.simpson@saama.com

908.313.7467

 

 

# # #

 

Post a Comment

You must be logged in to post a Comment.

FEEDBACK